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The purpose of this study was to evaluate the patient tolerance and eﬃcacy of delivering locoregional chemotherapy to metastatic
colorectal(MC)hepaticmetastasesviahepatictrans-arterialapproachusingirinotecanloadeddrugelutingbeads.Thisopen-label,
multi-center, single arm study included 30 MC patients, who had failed ﬁrst line therapy. Of the 57 total embolization sessions,
12 (21% of sessions) were associated with adverse reactions during or after the treatment. After a median followup of 9 months,
response rates by modiﬁed RECIST were 75% at 3 months and 66% at 6 months. Hepatic trans-arterial therapy using Irinotecan
loaded DC BeadTM was safe and eﬀective in the treatment of MCC as demonstrated by a minimal complication rate and acceptable
tumor response.
Copyright © 2009 Robert C. G. Martin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hepatic metastasis of colorectal cancer (MCC) is quite
common occurring at some time in 23% of all of the
190 000 colorectal patients diagnosed each year [1]. While
systemic chemotherapy can slow growth and even cause
regression of the size of the hepatic metastases, long-term
survival without local therapy is unlikely. Surgical resection
of hepatic metastases continues to remain the optimal ﬁrst
line treatment for hepatic colorectal metastases [2, 3]. Other
therapiesthathavebeenusedaretransarterialchemotherapy,
ethanol injection, cryotherapy, radiofrequency ablation, and
microwave ablation. The role of hepatic transarterial therapy
of hepatic colorectal metastases continues to evolve as
the technology evolves and experience with this technique
matures [4]. There have been recent reports of precision
transarterial therapy in metastatic colorectal cancer with
acceptable results [5, 6]. The concept of hepatic arterial
precision therapy is the ability to point direct doses of
chemotherapy directly to the hepatic tumors with the
subsequent systemic exposure.
Patients presenting with initial unresectable metastatic
colorectal metastasis either by a number of lesions or
extrahepatic metastatic disease have the beneﬁt of systemic
5 ﬂuorouracil-based chemotherapy with a combination of
oxaliplatin and/or irinotecan and oﬀers a high rate of
response (35%–50%) and a longer median survival (15–
20months) versus historical observation or 5 ﬂuorouracil
monotherapy alone [7–9]. However, patients who are refrac-
tory to 5FU-based systemic chemotherapy in combination
with oxaliplatin rarely show a durable clinically relevant
response rate for second or third line chemotherapy [10]. In2 Journal of Oncology
a majority of patients the most common site of refractory
progressioniswithintheliver[6].Thus,aminimallyinvasive
hepatic-directed therapy that could potentially accentuate
response rates as a monotherapy or in combination with
systemic therapy is greatly needed.
Intra-arterial hepatic chemotherapy has the potential to
accentuate both the palliation of patients and potentially
improve quality of life time. Given that hepatic colorectal
metastases are predominantly (95%–100%) fed by the
hepatic arterial system has the advantage of delivering high-
dose chemotherapy directly to the target lesion with minimal
systemic side eﬀects. This technique which has largely
been used in the treatment of hepatocellular carcinoma
is beginning to be expanded into other liver-dominant
metastatic disease [5, 6].
Thus, the aim of this study was to evaluate the initial
safety and eﬃcacy of irinotecan-loaded beads delivered by
hepatic transarterial approach for the treatment of unre-
sectable metastatic colorectal cancer.
2.MaterialsandMethods
An IRB-approved prospective multi-institutional open, non-
controlled repeat treatment registry was evaluated from Jan-
uary 2007 to October 2008 in which 30 patients presenting
with liver dominant metastatic colon cancer (MCC) to the
liver were treated with irinotecan drug eluting beads.
Patients were included for therapy if they were 18
years of age, of any race or sex, who had histologic or
radiologic proof of MCC to the liver, who were able to give
informed consent and were eligible for treatment. Patients
must have had an ECOG performance status score of less
than or equal to 2 with a life expectancy of greater than or
equal to 3 months, nonpregnant with an acceptable con-
traceptive in premenopausal women. Exclusion to therapy
was contraindication to angiographic and selective visceral
catheterization, signiﬁcant extrahepatic disease, representing
an imminent life-threatening outcome, greater than 75% of
hepatic parenchymal involvement, severe liver dysfunction,
pregnancy, and severe cardiac comorbidities. Only patients
with liver dominant (deﬁned as greater than 50% of the
overall total body disease burden) were considered for
treatment.
Standard pretherapy evaluation of patients with MCC
included at least a three-phase CT of the abdomen and
pelvis and chest roentgenogram at least one month prior
to treatment, with the use of PET scanning depending on
the institution and the availability of the technology for use.
Prior systemic chemotherapy of any type and duration was
allowed and was recorded.
Patients were followed for any treatment-related adverse
experiences for 30 days after each treatment and monitored
for survival for two years. All adverse events were recorded
per standards and terminology set forth by the Cancer Ther-
apy Evaluation Program Common Terminology Criteria for
Adverse Events, Version 3.0. Followup assessments included
a triphase CT scan of the liver within at least one to two
months from the treatment completion with the evaluation
of the enhancement pattern of the target lesion and tumor
response rates measured according to RECIST [11], EASL
[12], and modiﬁed RECIST [13] criteria.
2.1. Hepatic Angiogram. Diagnostic angiography was per-
formed by the interventional radiologist and consisted of
selective celiac and superior mesenteric arteriograms to
evaluate the hepatic arterial anatomy. Once it was evaluated
for the degree of hepatic tumor perfusion, the next step in
evaluation was to limit any type of extrahepatic perfusion of
the treatment. The most common branches that will lead to
extrahepaticdispositionoftreatmentaretherightgastricand
the gastroduodenal arteries which are controlled either prior
to infusion with coil embolization or at a minimum distal
catheter placement. In addition to this deﬁning the amount
of liver disease was integral to deﬁning both the number of
treatments and the type of catheter position and therapy that
would be performed. For ﬁnite number of lesions deﬁned as
less than four lesions, treatment plan existed for a minimum
of two dosing schedules of at least 50mg of irinotecan
to 100mg of irinotecan loaded in one-two DC/LC bead
vials of 100 to 300microns, 300 to 500microns, or 500 to
700microns (every four to eight weeks). For diﬀuse disease
a plan of a minimum of four-dosing schedule again of 50 to
100 mg (depending on the extent of tumor burden and the
extent of hepatic parenchyma reserve) again is loaded into
one-two DC/LC bead vials of the similar size as above with
the plan for at least two treatments per lobe with again every
three-to-four week dosing schedule, following toxicity, and
extending the interval if toxicity was seen with again planned
repeat CT scan three months from the ﬁrst dose to evaluate
tumor response.
Periprocedural medications including pain medications,
antibiotic prophylaxis, intra-arterial lidocaine, corticos-
teroids, and proton pump inhibitors were all performed at
the physician’s discretion.
The mixing of loaded DC/LC beads was performed with
nonionic contrast (approximately 50/50 dilution) prior to
injection.Aminimumof10cccontrastshouldbemixedwith
the loaded DC/LC bead to ensure smooth catheter delivery.
After appropriate mixing and removal of the uneluted
supernatant, a microcatheter is then placed based again on
the extent of liver disease. For a ﬁnite number of lesions, the
microcatheter is selectively placed (super selective) for the
ﬁrst DC/LC bead vial (a 100 to 300micron size) with initial
infusion with then a more proximal catheter placement
into the right or left hepatic artery for the second DC/LC
bead vial of the size choice (based on physician discretion).
For diﬀuse disease a more lobar infusion again using a
microcatheter into either the right or left artery, depending
on the bulk of disease, is performed with either any of
the three size DC/LC beads that the physician chooses to
evaluate.
Slow injection of the irinotecan-loaded DC/LC beads is
highly recommended to avoid reﬂux of embolic material.
In addition to that, particular attention into identifying the
cystic artery is recommended to ensure that the catheter
tip passed this point to avoid extrahepatic infusion intoJournal of Oncology 3
the gallbladder. Additional embolic material is not usually
followed after appropriate treatment but was up to the
physician’s discretion.
2.2. Drug Preparation. The saline suspension in the DC/LC
bead microsphere (DEB; Biocompatibles UK, Surrey, UK)
was removed and the beads were mixed with irinotecan
solutionatadoseof50mgper2mLatleastfourhoursbefore
the procedure depending on the dose that was planned to be
delivered.
Data was censored at the last recorded patient contact if
an endpoint was not reached. Recurrence was also evaluated
using serological markers and PET scan. A recurrence was
the reoccurrence of viable tumor by radiologic CT criteria
of a vascular mass. In the event of subsequent hepatic
therapy for recurrence of disease only the ﬁrst procedure was
used for the purposes of this study. Chi-square, Student’s t-
test, and Mann-Whitney’s U-test for nominal, continuous,
and ordinal variables were used to evaluate the association
of independent variables to surgical complications. Pro-
portional hazards analysis was performed on all variables
found signiﬁcant by univariate analysis. Relative risk (RR)
with 95% conﬁdence intervals was calculated as a measure
of association. Diﬀerences of P<. 05 were considered
signiﬁcant. Statistical analysis was performed using JMP
software (JMP; SAS Institute Inc., Cary, NC).
3. Results
3.1. Patient and Tumor Characteristics. A total of 30 patients
underwent 57 treatment sessions with the irinotecan drug-
eluting beads. There were 11 women and 19 men in this
study with a median age of 58 years (range 42–75). Past
medical histories were signiﬁcant for prior cardiac disease
in seven patient, prior pulmonary disease in three patients,
underlying diabetes in eight patients and prior alcohol abuse
in ﬁve patients with six patients having a prior smoking
history with a pack year median of 60 pack years (range
30–120). All of the study patients’ past medical histories
were negative for primary breast, carcinoid, renal, ovarian,
melanoma, sarcoma, and lung cancers.
All patients had had their colon primary resected.
Fifteenpatientshadundergoneeitherprioranatomichepatic
lobectomy or RFA to treat their initial disease.
The extent of liver metastasis had a majority of patients
with multiple lesions with a median number of lesions being
ﬁve (range 1–20) with 28 patients having a bilobar lesion
with the single largest target lesion being 5.0cm (range 1–
8cm). The extent of liver involvement had 14 patients with
less than 25% liver involvement, 15 patients with 26%–
50% liver involvement, and one patient with greater than
50% liver involvement. The total target lesion size (sum
of a maximum of ﬁve lesions) was 8.8cm (range 1.0 to
24.0cm). Sixteen patients had extrahepatic disease with 13
having involvement with small volume lung metastasis, one
with two retroperitoneal lymph nodes, one with a bony
metastasisatT1,andonewithpelviclymphnodeandsplenic
metastases.
3.2. Treatment. In review of the 57 treatment sessions, the
median number of treatments per patient was one (range
1–5). The right lobe was the most common lobe treated in
42 patients, left lobe alone in 15 patients with the remaining
being treated in a bilobar approach. The preprocedural dose
planning wasa median of 100mg (range50 to200) involving
am e d i a no fo n ev i a lw i t har a n g eo fo n et ot w ov i a l s .
The most common bead size was 100 to 300microns in
37 patients, 300 to 500micron beads in 25 patients, and
500 to 700micron beads in 18 patients. Forty six of the
57 treatment sessions received 100% of their planned dose
with the remaining 11 patients receiving a median of 80% of
the dose planned (range 50%–90%) because of early stasis
during treatment.
T h ed e g r e eo fﬂ o wo c c l u s i o ni n c l u d e dp a r t i a ls t a s i si n
22 patients, near stasis in 20 patients, and complete stasis
in 15 patients. Four patients did have a gel foam bland
embolization following their bead therapy because of small
aberrant posterior sector hepatic artery.
Periprocedural medications included antibiotics in 52 of
57 patients, most commonly being Kefsol, Levaquin, Flagyl,
and Ciproﬂoxacin. The antiemetic medication was utilized
in 57 of 57 patients with the most common medication
being Zofran in 42 treatment sessions with the addition
of Phenergan and/or Compazine based on the sensitivity
of the patient. All patients were given periprocedural and
postprocedural proton pump inhibitor or H2 blocker for
gastritis prevention. Periprocedural hepatic intra-arterial
Lidocaine was utilized prior to bead infusion in 35 of the
57 treatments, with systemic sedation being most commonly
Morphine and Versed with a smaller distribution of patients
receiving Dilaudid, Demerol, or Fentanyl. Postprocedure
anti-inﬂammatory was utilized in 26 of 57 treatments,
most commonly being Decadron or Toradol with a smaller
percentage given oral Vicoprofen.
In an evaluation of periprocedural outcomes a majority
of patients (60%) were treated as an outpatient setting
(deﬁned as less or equal to 23 hour admit) and on
multivariate analysis identiﬁed that the risk for admission
was found in patients who were receiving greater than or
equal to their third treatment or who had embolic product
followed in order to get to complete stasis after a successful
bead infusion. These results potentially demonstrate that
going to a complete stasis endpoint may lead to increase
adverse events without potential beneﬁts.
3.3. Patient Tolerance, Morbidity, and Mortality. Median
length of hospital stay for each treatment procedure was
23 hours with a range of 23 hours to 3 days. Pre- and
posttreatment WBC, hemoglobin, platelets, total bilirubin,
creatinine, albumin, and INR values were obtained. How-
ever, some isolated values for particular patients were unable
to be obtained. The most signiﬁcant change between the
pre- and posttreatment median lab values involved the WBC
count, which increased 25.9%, from 7.2 to 9.1. Pre- and
posttreatment median hemoglobin values were 12.1 and
12, respectively—representing a 0.8% decrease from pre- to
posttreatment levels. Pre- and posttreatment median platelet
valueswere241and237.5,respectively—representinga1.5%4 Journal of Oncology
decrease from pre- to posttreatment levels. Pre- and
posttreatment median bilirubin values were 0.6 and 0.7,
respectively—representing a 16.7% increase from pre- to
posttreatment levels. Pre- and posttreatment median cre-
atinine values were 0.9 and 0.8, respectively—representing
an 11.1% decrease from pre- to posttreatment levels. Pre-
and posttreatment median albumin values were 4 and
3.8, respectively—representing a 5% decrease from pre- to
posttreatment levels. Pre- and posttreatment median INR
values did not change and were 1 and 1, respectively.
Of the 57 total embolization sessions, 12 (21% of
sessions) were associated with adverse reactions during or
after the treatment. However, because many patients had
more than one treatment session, 9 patients suﬀered adverse
reactions during or after their treatment. 4 of the 9 patients
with adverse reactions had reactions that were rated as
grade 3, with 1 subsequent death. However, the remaining
5 patients had adverse reactions to treatment that were only
grades 1 and 2.
The most common adverse event 6 (50%) was postem-
bolic syndrome type symptoms of nausea, vomiting, and,
hypertension of either grade 1 or grade 2 in severity that
required hospitalization and subsequent treatment. Other
treatment-related events included port infection (grade 3),
gastritis(grade1),dehydration(grade2),cholecystitis(grade
3), and hypertension (grade 2), that all resolved and were felt
tobepossiblyorprobablyrelatedtotheirinotecantreatment.
One patient did have an adverse event of liver dys-
function/failure (grade 3 adverse reaction) the day after
treatment. More speciﬁcally, the patient’s bilirubin increased
from baseline 2.9 to 3.4 on postoperative day 1. On
postoperative day 2, the patient’s bilirubin had decreased to
3.0andsubsequentlythispatient’sliverdysfunctionresolved.
This reaction was thought to be possibly related to the
embolization treatment.
One patient had an SAE of liver dysfunction, found 28
days after treatment. The patient expired from ongoing liver
dysfunction 30 days after the SAE was observed. The treating
physician felt that this event was possibly related to the
treatment or device. The patient had been treated with 31
total cycles of FOLFOX, 9 cycles of FOLFIRI, and 12 cycles
of Avastin and had a prior percutaneous RFA prior to bead
therapy. The patient was given a single treatment of 2 vials
of DC/LC Bead loaded with 200mg Irinotecan. The patient
had a 3-day hospital stay for nausea and then was discharged
homewithoutincidentuntilhereturnedonday28.Ptwas52
years of age, had a preoperative bilirubin of 1.9, INR of 2.0,
and underwent treatment to the right lobe, with one vial of
300–500um and one vial of 500–700um size beads, through
a lobar infusion with near stasis after bead infusion. His
medications were cipro and ﬂaygy after, with Zofran during
the procedure, and an epidural for pain management. His
liver involvement was 4 total lesions in seg 5–8, largest lesion
4.2cm, with 26%–50% liver involvement, with total targets
lesion size of 12.9cm, with extrahepatic disease involving the
pancreas, spleen, and lung.
3.4. Followup and Tumor Response. After a median followup
of nine months on all 30 patients treated, response rate
Table 1: Clinical demographic data in 30 colorectal metastasis
patients treated with LC Bead.
Demographic n = (%)
Caucasian 24 (80%)
African American 5 (19%)
Asian 1 (1%)
Age, median (range) 55 (40–75)
Gender
Male 19 (63%)
Female 11 (47%)
Prior chemotherapy
FOLFOX 25
FOLFIRI 11
Avastin 27
Xeloda 7
Erbitux 3
5FU 4
Vectibex 2
Adverse Events in 57 total bead treatments
Cholecystititis 1 (2%) Grade 3
Dehydration 1 (2%) Grade 2
Gastritis 1 (2%) Grade 1
Hypertension 3 (5%) Grades 1–2
Infection 1 (2%) Grade 1
Liver dysfunction/failure 2 (4%) Grades 3,5
Nausea 5 (9%) Grades 1–2
Pain 1 (2%) Grade 1
Vomiting 3 (5%) Grades 1–2
at three months by modiﬁed RECIST was seen in 75% of
patients and at six months in 66% of patients. Similarly all
30 patients demonstrated a great than or equal 50% drop
in their CEA levels at 3 months that was sustain at 6-month
evaluation.
3.5. Discussion. The multidisciplinary management of
metastatic colorectal is becoming far more complex and
far more collaborative in the optimal treatment of patients
with metastatic colorectal cancer. Given the ever increasing
incidence of this disease with an estimated 90 000 to
100 000 new cases of metastatic colorectal cancer being
diagnosed each year in the United States, this type of
multidisciplinary management and collaboration is integral
to the success and quality of life of the patient. These
results presented demonstrate that precision hepatic arterial
Irinotecan therapy is a safe and eﬀective treatment in
the management of patients with metastatic colorectal.
These results demonstrate a minimal quality of life side
eﬀect and potential optimal response rates and, therefore,
i m p r o v e dp r o g r e s s i o n - f r e es u r v i v a la n do v e r a l ls u r v i v a li n
the management of this challenging disease. This initial
pilot evaluation conﬁrms the activity of this device in the
management of colorectal cancer.Journal of Oncology 5
Hepatic-directed therapy in the management of
metastatic colorectal cancer is a well-established therapy
ranging from hepatic arterial infusion pumps [14]t o
conventional TACE [15] to implantable infusaports [16].
The rationale and clinical success of hepatic arterial therapy
is well established but can be plagued by signiﬁcant adverse
events including both the need for surgical intervention
[17], biliary sclerosis [18], signiﬁcant systemic exposure
[19], and catheter dislodgement and misplacement leading
to inadvertent aqueous extrahepatic infusion. LC/DC
bead loaded with Irinotecan has potential advantages that
overcome all of the limitations of prior hepatic arterial-
directedtherapies.Itisamore precision-directed devicewith
minimal-to-no systemic side eﬀects as has been reported in
prior in vitro and in vivo studies [20, 21]. The data presented
here demonstrated that we had no evidence of Irinotecan
systemic adverse events and that all of our adverse events
were related to the hepatic-directed therapy. All adverse
events, on review, appear to be technically related that can
be improved with adjustments in technique.
The most common adverse events were periprocedural
pain,nausea,andhypertension.Asdemonstratedinthisdata
only a subset of patients received preinfusion hepatic arterial
Lidocaine. In a review of the data, this demonstrated to be a
signiﬁcant predictor of reduction or actuallysuppressing this
adverse event when the use of 2 to 4cc of 1% plain lidocaine
is infused into the hepatic arterial system prior to bead infu-
sion. It is well established that the DC/LC Irinotecan bead
doesleadtoasmall(5%–10%)chemotherapyburstoninitial
infusion into the liver and the surrounding parenchyma. The
intra-arterial lidocaine has been demonstrated to be eﬀective
in reducing the symptoms of this burst, such that patients
are able to tolerate the therapy similar to other established
hepatic-directed therapies. The intra-arterial lidocaine has
now become a standard of pretreatment technique when
utilizing the Irinotecan bead for metastatic colorectal or any
other type of metastatic disease in which the device is chosen
to be utilized. Similar to that, one of other more common
adverse events was periprocedural nausea, seen to a greater
extent when anecdotally compared to conventional TACE or
even prior Yttrium therapy. Eﬀective management of this has
now been achieved with now a pretreatment infusion of a
higher dose of Zofran that is initiated approximately 15 to 30
minutes prior to procedure with the eﬀective amelioration of
this symptom through a more aggressive type of antiemetic
treatment. The last, more common, adverse event seen was
also hypertension which appeared to be refractory to the
more established interventional drugs that are commonly
used, those being lopressor and nitroprusside, and is found
to be far more sensitive when vasotec is utilized when
periprocedural hypertension is seen.
Thus in conclusion chemoembolization using Irino-
tecan-loaded bead was safe and eﬀective in the treatment
of MCC as demonstrated by a minimal complication rate,
acceptable tumor response, and sustained reduction of
CEA levels. Further larger studies are needed to conﬁrm
this data and establish where hepatic arterial precision
chemotherapy should be utilized in the algorithm of the
metastatic colorectal cancer patient.
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